
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.2.3, mkdocs-material-7.3.4">
    
    
      
        <title>Sjögren's syndrome - CNUH.Rheumatology</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.db9e7362.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.3f5d1f46.min.css">
        
      
    
    
    
      
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lato:300,400,400i,700%7C&display=fallback">
        <style>:root{--md-text-font-family:"Lato";--md-code-font-family:""}</style>
      
    
    
    
      <link rel="stylesheet" href="../../stylesheets/extra.css">
    
      <link rel="stylesheet" href="../../stylesheets/table_style.css">
    
    
      


    
    
  </head>
  
  
    
    
    
    
    
    <body dir="ltr" data-md-color-scheme="" data-md-color-primary="" data-md-color-accent="indigo">
  
    
    <script>function __prefix(e){return new URL("../..",location).pathname+"."+e}function __get(e,t=localStorage){return JSON.parse(t.getItem(__prefix(e)))}</script>
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#1-historical-perspective" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="CNUH.Rheumatology" class="md-header__button md-logo" aria-label="CNUH.Rheumatology" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54z"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            CNUH.Rheumatology
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Sjögren's syndrome
            
          </span>
        </div>
      </div>
    </div>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5z"/></svg>
      </label>
      
<div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5z"/></svg>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" aria-label="Clear" tabindex="-1">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-tabs__inner md-grid">
    <ul class="md-tabs__list">
      
        
  
  


  <li class="md-tabs__item">
    <a href="../.." class="md-tabs__link">
      Home
    </a>
  </li>

      
        
  
  
    
  


  
  
  
    

  
  
  
    <li class="md-tabs__item">
      <a href="../../intro/approach/" class="md-tabs__link md-tabs__link--active">
        Docs
      </a>
    </li>
  

  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="CNUH.Rheumatology" class="md-nav__button md-logo" aria-label="CNUH.Rheumatology" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54z"/></svg>

    </a>
    CNUH.Rheumatology
  </label>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
      

  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        Home
      </a>
    </li>
  

    
      
      
      

  
  
    
  
  
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_2" type="checkbox" id="__nav_2" checked>
      
      
      
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
          
        
      
      
        <label class="md-nav__link" for="__nav_2">
          Docs
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Docs" data-md-level="1">
        <label class="md-nav__title" for="__nav_2">
          <span class="md-nav__icon md-icon"></span>
          Docs
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_2_1" type="checkbox" id="__nav_2_1" >
      
      
      
        
          
        
          
        
          
        
      
      
        <label class="md-nav__link" for="__nav_2_1">
          Introduction
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Introduction" data-md-level="2">
        <label class="md-nav__title" for="__nav_2_1">
          <span class="md-nav__icon md-icon"></span>
          Introduction
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../intro/approach/" class="md-nav__link">
        Approach
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../intro/criteria/" class="md-nav__link">
        Criteria
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../intro/div/" class="md-nav__link">
        div
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../approach/" class="md-nav__link">
        Dx. Tests & Meds
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../ra/ra/" class="md-nav__link">
        Rheumatoid Arthritis
      </a>
    </li>
  

            
          
            
              
  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_2_4" type="checkbox" id="__nav_2_4" >
      
      
      
        
          
        
          
        
      
      
        <label class="md-nav__link" for="__nav_2_4">
          SLE & APS 
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="SLE & APS " data-md-level="2">
        <label class="md-nav__title" for="__nav_2_4">
          <span class="md-nav__icon md-icon"></span>
          SLE & APS 
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../sle%26aps/sle/" class="md-nav__link">
        SLE
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../sle%26aps/aps/" class="md-nav__link">
        APS
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

            
          
            
              
  
  
    
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" data-md-toggle="toc" type="checkbox" id="__toc">
      
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          Sjögren's syndrome
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        Sjögren's syndrome
      </a>
      
        
<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-historical-perspective" class="md-nav__link">
    1. Historical Perspective
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2" class="md-nav__link">
    2. 정의 및 분류
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3" class="md-nav__link">
    3. 역학 및 발병 인자
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4" class="md-nav__link">
    4. 병인기전
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5" class="md-nav__link">
    5. 임상증상
  </a>
  
    <nav class="md-nav" aria-label="5. 임상증상">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#5-1-glandular-manifestation" class="md-nav__link">
    5-1. 주요 증상 (Glandular manifestation) :
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#5-2-extraglandular-manifestation" class="md-nav__link">
    5-2. 기타 증상 (Extraglandular manifestation)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6" class="md-nav__link">
    6. 검사소견과 진단
  </a>
  
    <nav class="md-nav" aria-label="6. 검사소견과 진단">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#6-1" class="md-nav__link">
    6-1. 기본 개념
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-2" class="md-nav__link">
    6-2. 혈액검사
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-3" class="md-nav__link">
    6-3. 기타검사
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-4" class="md-nav__link">
    6-4. 분류기준
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-5" class="md-nav__link">
    6-5. 감별진단 (배제)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7" class="md-nav__link">
    7. 치료원칙
  </a>
  
    <nav class="md-nav" aria-label="7. 치료원칙">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#7-1" class="md-nav__link">
    7-1. 요약
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#7-2-disease-activity-severity" class="md-nav__link">
    7-2. Disease activity &amp; severity
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8" class="md-nav__link">
    8. 경과와 예후
  </a>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../SSc/ssc/" class="md-nav__link">
        Systemic Sclerosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../myopathy/iim/" class="md-nav__link">
        Idiopathic Inflammatory Myositis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../spondyloarthropathy/spa/" class="md-nav__link">
        Spondylooarthropathy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../vasculitis/vasculitis/" class="md-nav__link">
        Vasculitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../crystalopathy/gout/" class="md-nav__link">
        Crystalopathy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../osteoporosis/osteoporosis/" class="md-nav__link">
        Osteoporosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../pain/pain/" class="md-nav__link">
        Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../other_diseases/others/" class="md-nav__link">
        Other diseases
      </a>
    </li>
  

            
          
            
              
  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_2_14" type="checkbox" id="__nav_2_14" >
      
      
      
        
          
        
          
        
      
      
        <label class="md-nav__link" for="__nav_2_14">
          Miscellaneous
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Miscellaneous" data-md-level="2">
        <label class="md-nav__title" for="__nav_2_14">
          <span class="md-nav__icon md-icon"></span>
          Miscellaneous
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../misc/perioperative/" class="md-nav__link">
        Perioperative
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../../misc/misc/" class="md-nav__link">
        Misc
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    
<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-historical-perspective" class="md-nav__link">
    1. Historical Perspective
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2" class="md-nav__link">
    2. 정의 및 분류
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3" class="md-nav__link">
    3. 역학 및 발병 인자
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4" class="md-nav__link">
    4. 병인기전
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5" class="md-nav__link">
    5. 임상증상
  </a>
  
    <nav class="md-nav" aria-label="5. 임상증상">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#5-1-glandular-manifestation" class="md-nav__link">
    5-1. 주요 증상 (Glandular manifestation) :
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#5-2-extraglandular-manifestation" class="md-nav__link">
    5-2. 기타 증상 (Extraglandular manifestation)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6" class="md-nav__link">
    6. 검사소견과 진단
  </a>
  
    <nav class="md-nav" aria-label="6. 검사소견과 진단">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#6-1" class="md-nav__link">
    6-1. 기본 개념
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-2" class="md-nav__link">
    6-2. 혈액검사
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-3" class="md-nav__link">
    6-3. 기타검사
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-4" class="md-nav__link">
    6-4. 분류기준
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#6-5" class="md-nav__link">
    6-5. 감별진단 (배제)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7" class="md-nav__link">
    7. 치료원칙
  </a>
  
    <nav class="md-nav" aria-label="7. 치료원칙">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#7-1" class="md-nav__link">
    7-1. 요약
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#7-2-disease-activity-severity" class="md-nav__link">
    7-2. Disease activity &amp; severity
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8" class="md-nav__link">
    8. 경과와 예후
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          <div class="md-content" data-md-component="content">
            <article class="md-content__inner md-typeset">
              
                
                
                  <h1>Sjögren's syndrome</h1>
                
                <p>눈마름과 입마름 증상을 호소하며, 병리적으로는 외분비샘의 림프구침윤 및 파괴로 인한 기능 저하를 특징으로 하는 자가면역질환</p>
<h2 id="1-historical-perspective">1. Historical Perspective</h2>
<hr />
<p>(1888) Johann von Mikulicz-Radecki : 눈물샘, 이하선, 턱밑샘의 양측성, 무통성 종창 발표</p>
<p>(1925) Henri Gourgerot : 타액선 위축 및 눈, 입, 질의 건조를 동반한 케이스 발표</p>
<p>(1933) Henrik Sjogren : 19개의 Keratoconjunctivitis sicca 케이스 (2건은 침샘 부종 포함)</p>
<p>(1953) Morgan &amp; Castleman : 18개의 눈물샘/침샘 비대 Bx. 결과 발표</p>
<p>(1960) Joseph J. Bunim  et al. : 40명의 Sjogren syndrome case 발표</p>
<p>(1965) NIH : 다른 CTD가 없는 Sicca syndrome 환자의 75%에서 ANA (+), Anti-Ro/La (+/+)</p>
<p>(1970) minor labial biopsy &amp; focus score</p>
<p><br></p>
<h2 id="2">2. 정의 및 분류</h2>
<ol>
<li>Sjogren's syndrome = Keratoconjunctivitis sicca (KCS) + Xerostomia<ul>
<li>Keratoconjunctivitis sicca (KCS) = dryness of the cornea and conjunctiva</li>
<li>Xerostomia = subjective symptoms of dry mouth</li>
</ul>
</li>
<li>분류<ul>
<li>Primary : KCS or Xerostomia without other CTD + Serologic and/or histopathologic criteria</li>
<li>Secondary : KCS or Xerostomia with other CTD (RA, SLE, SSc, PM/DM, Vasculitis, etc.)</li>
</ul>
</li>
</ol>
<p><br></p>
<h2 id="3">3. 역학 및 발병 인자</h2>
<hr />
<ol>
<li>40~50대, M:F = 14.5:1</li>
<li>유병률 : 0.1~4.6% </li>
<li>Secondary SS : RA에서는 4~31%, SLE에서는 6~19%, SSc에서는 14~21%</li>
</ol>
<p><br></p>
<h2 id="4">4. 병인기전</h2>
<hr />
<ol>
<li>병리 소견 : 침샘의 림프구 침윤 (주로 T cell or B cell, DC/Plasma cell/macrophages)</li>
<li>유전적 요인 + 환경적 요인 + 면역학적 요인</li>
</ol>
<p><br></p>
<h2 id="5">5. 임상증상</h2>
<hr />
<h3 id="5-1-glandular-manifestation">5-1. 주요 증상 (Glandular manifestation) :</h3>
<ol>
<li>건조증상 : 대부분 8~10년 동안 느리게 진행<ol>
<li>눈 : 건성각막결막염 (keratoconjunctivitis sicca) - lacrimal gland의 만성 염증때문에 눈물분비가 감소하여 conjunctival &amp; bulbar epithelium을 파괴함.</li>
<li>입 : 침분비 감소로 인한 구강건조증 - 씹고 삼키는데 어려움, 맛의 변화, 장시간 말하기의 어려움, 충치, 갈라진 치아, 구강 칸디다증</li>
</ol>
</li>
<li>귀밑샘/큰침샘의 비대 : 전체  primary SS 환자의 약 1/4 정도. 건조된 점액이 일시적으로 주요 관을 막아서 비대해짐.</li>
</ol>
<h3 id="5-2-extraglandular-manifestation">5-2. 기타 증상 (Extraglandular manifestation)</h3>
<table class="basic">
<thead>
  <tr>
    <th>System</th>
    <th>증상</th>
  </tr>
</thead>
<tbody>
  <tr>
    <td>Fatigue (70%)</td>
    <td>SS 자체 증상 또는 Depression, anxiety, FMS, sleep deficit 때문일 수도 있다.</td>
  </tr>
  <tr>
    <td>Raynaud's phenomenon</td>
    <td>Sicca symptom 시작 몇 년 전부터 선행함. Digital ulcer는 드물다.</td>
  </tr>
  <tr>
    <td>Skin</td>
    <td>건성 피부, 눈꺼풀 피부염, 각질염, 환형 홍반, 자반병, Cutaneous vasculitis<br>Livedo reticularis - 대개 다른 extraglandular manifestation에 동반<br>Vasculitis 양상은 medium/small vessel vasculitis 양상과 유사 (Deep perivascular lymphocytic infiltrate without epidermal changes)</td>
  </tr>
  <tr>
    <td>Joint (45%)</td>
    <td>1/3 에서는 관절증상이 SS 증상보다 먼저 발생</td>
  </tr>
  <tr>
    <td>Lung (11%)</td>
    <td>주로 ILD (NSIP, UIP pattern)</td>
  </tr>
  <tr>
    <td>Kidney (5%)</td>
    <td>TIN, Type 1 RTA, GN (주로 lymphoma와 관련), NDI</td>
  </tr>
  <tr>
    <td>GI </td>
    <td>Dysphagia, dyspepsia, Esophageal achalasia, PBC</td>
  </tr>
  <tr>
    <td>NR </td>
    <td>depression, mild cognitive disorder, peripheral neuropathy</td>
  </tr>
  <tr>
    <td>CV </td>
    <td>뇌혈관/심근경색 위험 증가</td>
  </tr>
  <tr>
    <td>Thyroid </td>
    <td>Anti-Thyroglobin Ab (+), TSH elevation</td>
  </tr>
  <tr>
    <td>Lymphoma </td>
    <td>NHL (지속적인 침샘비대, 자색반, 백혈구감소증, ectopic germinal center) - MALT, DLBCL 등</td>
  </tr>
</tbody>
</table>

<p><br></p>
<h2 id="6">6. 검사소견과 진단</h2>
<hr />
<h3 id="6-1">6-1. 기본 개념</h3>
<ol>
<li>주관적인 증상이 있는가? → 건성안 / 구강건조증</li>
<li>자가면역성이 있는가? (=자가항체가 나오는가?) → Anti-Ro/SSa</li>
<li>그 증상을 검사로 증명할 수 있는가? → Shirmer test, OSS / Sialometry, Sialography, Scintigraphy, </li>
<li>기타 검사 → US / MRI</li>
<li>Minor labial salivary gland biopsy : focus score ≥1<ul>
<li>Focus = 50개 이상의 lymphocyte cluster</li>
<li>greater than or equal to 1 per 4 mm 2 of tissue 일 때 양성</li>
<li>focus score &gt; 3이면 lymphoma risk가 올라간다.</li>
<li>SS 진단 뿐만 아니라 MALToma, sarcoidosis, IgG4-related ds. 감별에도 유용하다.</li>
</ul>
</li>
</ol>
<p>** 임상적/Lab finding 이 명확하다면 굳이 biopsy를 하지 않아도 된다.</p>
<p>** 증상은 있는데 Anti-Ro (-) or low titer면 biopsy를 해야 한다.</p>
<p>** 건성안이 있는 환자의 대부분은 쇼그렌이 아니다.</p>
<p>** 일반 인구의 약 25%가 구강 건조 증상을 가지고 있고, 대부분은 쇼그렌이 아니다.</p>
<h3 id="6-2">6-2. 혈액검사</h3>
<ol>
<li>anemia, leukopenia</li>
<li>ESR elevation</li>
<li>Hypergammmaglobulinemia : 80%</li>
<li>Low C3, C4 : 5~10%</li>
<li>Anti-Ro/La Ab., RF, ANA, Tg, TPO, Anti-mitochondrial ab., Anti-Muscarin3 Rc Ab.</li>
</ol>
<p>** Anti-La Ab.는 이제 더 이상 임상적으로 진단에 유용하지 않음.</p>
<p>** Anti-Ro Ab.는 충분한 역가라야 한다.</p>
<h3 id="6-3">6-3. 기타검사</h3>
<ol>
<li>눈검사<ol>
<li>schirmer test &lt; 5mm</li>
<li>Rose bengal stain : keratoconjunctivitis sicca &gt; 3 (아파서 이제 안쓴다)</li>
<li>OSS : lissamine greein or fluorescein stain &gt;= 3</li>
<li>Tear film break-up test :</li>
</ol>
</li>
<li>침샘검사<ol>
<li>Sialometry</li>
<li>Sialography</li>
<li>Scintigraphy</li>
<li>minor labial salivary gland biopsy : gold standard</li>
</ol>
</li>
</ol>
<h3 id="6-4">6-4. 분류기준</h3>
<details class="note"><summary>2016 ACR/EULAR Primary Sjögren's Syndrome classification criteria</summary><div class="tabbed-set tabbed-alternate" data-tabs="1:2"><input checked="checked" id="__tabbed_1_1" name="__tabbed_1" type="radio" /><input id="__tabbed_1_2" name="__tabbed_1" type="radio" /><div class="tabbed-labels"><label for="__tabbed_1_1">ENG</label><label for="__tabbed_1_2">국문</label></div>
<div class="tabbed-content">
<div class="tabbed-block">
<p><table class="md_basic_2">
 <thead>
 <tr class="header">
    <th colspan="2">The classification of primary SS applies to any individual who meets the inclusion criteria§,<br>does not have any of the conditions listed as exclusion criteria¥</th>
 </tr>
 </thead>
 <tbody>
 <tr style="background-color: rgba(0, 0, 0, 0.2)">
    <td colspan="2">§ Inclusion criteria : These criteria are applicable to any patient with at least one symptom of ocular or oral dryness, defined as a positive response to at least one of the following questions</td></tr>
    <tr>
    <td colspan="2">(1) Have you had daily, persistent, troublesome dry eyes for more than three months?; <br>(2) Do you have a recurrent sensation of sand or gravel in the eyes?; <br>(3) Do you use tear substitutes more than three times a day?; <br>(4) Have you had a daily feeling of dry mouth for more than three months?; <br>(5) Do you frequently drink liquids to aid in swallowing dry food? <br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or in whom there is suspicion of SS from the EULAR SS Disease Activity Index questionnaire (at least one domain with positive item).</td>
 </tr>
 <tr>
 <td colspan="2" style="background-color: rgba(0, 0, 0, 0.2)">¥ Exclusion criteria  Prior diagnosis of any of the following conditions would exclude diagnosis of SS and participation in SS studies or therapeutic trials because of overlapping clinical features or interference with criteria tests</td></tr>
 <tr>
    <td colspan="2">(1) History of head and neck radiation treatment<br>(2) Active hepatitis C infection (with positive PCR)<br>(3) Acquired immunodeficiency syndrome<br>(4) Sarcoidosis<br>(5) Amyloidosis<br>(6) Graft-versus-host disease<br>(7) IgG4-related disease</td>
 </tr>
 <tr><td colspan=2, style=background-color:white></td></tr>
 </tbody><br />
 <thead>
 <tr class="header">
    <th colspan=2>The classification of primary SS : A score ≥4 when the weights from the five criteria items are summed.</th>
 </tr>
 </thead>
 <tbody>
 <tr style="background-color: rgba(0, 0, 0, 0.2)">
    <td>Item</td>
    <td style=text-align:center>Weight/score</td>
 </tr>
 <tr>
    <td class="term">Labial salivary gland with focal lymphocytic sialadenitis and focus score of ≥1 foci/4 mm2<em></td>
    <td style=text-align:center>3</td>
 </tr>
 <tr>
    <td class="term">Anti-Ro/SSA positive</td>
    <td style=text-align:center>3</td>
 </tr>
 <tr>
    <td class="term">Ocular staining score ≥5 (or van Bijsterveld score ≥4) in at least one eye¶Δ</td>
    <td style=text-align:center>1</td>
 </tr>
 <tr>
    <td class="term">Schirmer test ≤5 mm/5 minutes in at least one eye¶</td>
    <td style=text-align:center>1</td>
 </tr>
 <tr>
    <td class="term">Unstimulated whole saliva flow rate ≤0.1 mL/minute¶◊</td>
    <td style=text-align:center>1</td>
 </tr>
 <tr>
    <td colspan=2, style=background-color:white></td>
 </tr>
 <tr style="background-color: rgba(0, 0, 0, 0.2)">
    <td colspan=2>Note</td>
 <tr>
    <td colspan="2"></em> Labial salivary gland with focal lymphocytic sialadenitis and focus score ≥1 foci/4 mm2. The histopathologic examination should be performed by a pathologist with expertise in the diagnosis of focal lymphocytic sialadenitis and focus score count, following a protocol described by Daniels, et al[1].</td>
 </tr>
 <tr>
    <td colspan="2">¶ Patients who are normally taking anticholinergic drugs should be evaluated for objective signs of salivary hypofunction and ocular dryness after a sufficient interval without these medications in order for these components to be a valid measure of oral and ocular dryness.</td>
 </tr>
 <tr>
    <td colspan="2">Δ Ocular staining score described by Whitcher, et al[2]; van Bijsterveld score described by van Bijsterveld[3].</td>
 </tr>
 <tr>
    <td colspan="2">◊ Unstimulated whole saliva flow rate measurement described by Navazesh and Kumar[4].</td>
 </tr>
 </tbody>
 </table></p>
</div>
<div class="tabbed-block">
<p><table class="md_basic_2">
 <thead>
 <tr class="header">
    <th colspan="2">일차성 쇼그렌증후군의 분류는 다음 포함기준§을 만족하면서,<BR>배제기준¥에 나열된 조건 중 어느 것도 해당되지 않은 사람에게 적용한다.</th>
 </tr>
 </thead>
 <tbody>
 <tr style="background-color: rgba(0, 0, 0, 0.2)">
    <td colspan="2">§ 포함기준 : 이 기준은 안구 건조 또는 구강 건조의 증상이 하나 이상 있는 모든 환자에게 적용되며, 안구 건조 또는 구강 건조의 증상은 다음 질문 중 하나 이상에 대해 긍정적으로 대답하는 것으로 정의된다.</td></tr>
    <tr>
    <td colspan="2">(1) 매일, 지속되는, 불편한 안구 건조증이 3개월 이상 지속되었나?<br>(2) 눈에 모래나 자갈이 들어 있는 느낌이 반복적으로 발생하는가?<br>(3) 하루에 3회 이상 인공 눈물을 사용하는가?<br>(4) 매일 구강 건조 증상을 느끼는 것이 3개월 이상 지속되었나?<br>(5) 건조한 음식을 삼키는데 도움을 받기 위해 음료수를 자주 마시는가?<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;또는 ESSDAI 설문지에서 쇼그렌증후군이 의심되는 환자 (양성 항목이 있는 적어도 하나의 도메인).</td>
 </tr>
 <tr>
 <td colspan="2" style="background-color: rgba(0, 0, 0, 0.2)">¥ 배제기준 : 다음 조건 중 하나라도 예전에 진단받은 적이 있다면 분류기준상의 항목과 중복되는 임상적 특징이나 상호간섭 때문에 쇼그렌증후군의 진단 및 연구 또는 치료 시험 참여를 배제한다.</td></tr>
 <tr>
    <td colspan="2">(1) 두경부 방사선치료의 병력<br>(2) 활동성 C형간염 감염 (PCR양성)<br>(3) AIDS<br>(4) 사르코이드증<br>(5) 아밀로이드증<br>(6) GVHD<br>(7) IgG4-연관 질환</td>
 </tr>
 <tr><td colspan=2, style=background-color:white></td></tr>
 </tbody><br />
 <thead>
 <tr class="header">
    <th colspan=2>일차성 쇼그렌증후군 분류 : 다섯 항목의 비중/점수의 합이 4 이상일 때</th>
 </tr>
 </thead>
 <tbody>
 <tr style="background-color: rgba(0, 0, 0, 0.2)">
    <td>항목</td>
    <td style=text-align:center>비중/점수</td>
 </tr>
 <tr>
    <td class="term">입술 침샘 조직검사상 국소 림프구성 침샘염이 확인되고 focus score ≥1 foci/4 mm<sup>2</sup> &#42;</td>
    <td style=text-align:center>3</td>
 </tr>
 <tr>
    <td class="term">Anti-Ro/SSA 양성</td>
    <td style=text-align:center>3</td>
 </tr>
 <tr>
    <td class="term">최소한 한 개의 눈에서 안염색점수(Ocular staining score) ≥5 (또는 van Bijsterveld score ≥4)¶Δ</td>
    <td style=text-align:center>1</td>
 </tr>
 <tr>
    <td class="term">최소한 한 개의 눈에서 쉬르머검사 ≤5 mm/5 minutes ¶</td>
    <td style=text-align:center>1</td>
 </tr>
 <tr>
    <td class="term">비자극 침분비 검사 ≤0.1 mL/minute¶◊</td>
    <td style=text-align:center>1</td>
 </tr>
 <tr>
    <td colspan=2, style=background-color:white></td>
 </tr>
 <tr style="background-color: rgba(0, 0, 0, 0.2)">
    <td colspan=2>참고</td>
 <tr>
    <td colspan="2">* 입술 침샘 조직검사상 국소 림프구성 침샘염이 확인되고 focus score ≥1 foci/4 mm2. 조직병리검사는 국소 림프구성 침샘염과 focus score 진단을 전문으로 하는 병리학자에 의해 수행되어야 하며, 해당 검사는 Daniels, et al.이 설명한 프로토콜을 따름.</td>
 </tr>
 <tr>
    <td colspan="2">¶ 환자들 중 평소에 항콜린성약제를 복용하는 경우에는, 이 항목이 구강과 안구 건조증을 적절히 측정하는 요소가 되도록 하기 위해 약제를 중단한 후 충분한 기간이 지난 후에 침샘의 기능부전과 안구 건조 증상의 객관적 징후를 평가받아야 함.</td>
 </tr>
 <tr>
    <td colspan="2">Δ 안염색점수(Ocular staining score)는 by Whitcher, et al에서 설명되고; van Bijsterveld score는van Bijsterveld에 의해 설명됨.</td>
 </tr>
 <tr>
    <td colspan="2">◊ 비자극 침분비 검사는 Navazesh and Kumar에 의해 설명됨.</td>
 </tr>
 </tbody>
 </table></p>
</div>
</div>
</div>
</details>
<details class="note"><summary>2012 SICCA &amp; ACR Sjögren's Syndrome classification criteria</summary><div class="tabbed-set tabbed-alternate" data-tabs="2:2"><input checked="checked" id="__tabbed_2_1" name="__tabbed_2" type="radio" /><input id="__tabbed_2_2" name="__tabbed_2" type="radio" /><div class="tabbed-labels"><label for="__tabbed_2_1">ENG</label><label for="__tabbed_2_2">국문</label></div>
<div class="tabbed-content">
<div class="tabbed-block">
<p><BR>
 <table class="md_basic_2">
 <thead>
    <tr class="header">
       <th>The classification of Sjögren syndrome (SS), which applies to individuals with signs or symptoms that may be suggestive of SS, will be met in patients who have at least two of the following three objective features</th>
    </tr>
 </thead>
 <tbody>
    <tr>
       <td> 1. Positive serum anti-SSA/Ro and/or anti-SSB/La or (positive RF and ANA titer ≥1:320)</td>
    </tr>
    <tr>
       <td> 2. Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score ≥1 focus/4 mm2†</td>
    </tr>
    <tr>
       <td> 3. Keratoconjunctivitis sicca with ocular staining score ≥3 (assuming that individual is not currently using daily eye drops for glaucoma and has not had corneal surgery or cosmetic eyelid surgery in the past 5 years)‡</td>
    </tr>
    </thead>
 <tbody>
    <tr class="blank">
       <td></td>
    </tr>
 </tbody>
 <thead>
    <tr>
       <th>Prior diagnosis of any of the following conditions would exclude participation in SS studies or therapeutic trials because of overlapping clinical features or interference with criteria tests:</th>
    </tr>
 </thead>
 <tbody>
    <tr>
       <td> History of head and neck radiation treatment<br>Hepatitis C infection<br>Acquired immunodeficiency syndrome<br>Sarcoidosis<Br>Amyloidosis<br>Graft-versus-host disease<br>IgG4-related disease</td>
    </tr>
 </tbody>
 <tbody>
    <tr class=blank>
       <td colspan=2></td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.2)">
       <td colspan=2>Note</td>
    </tr>
    <tr>
       <td>*We excluded participants with rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and other connective tissue disease from these analyses because there were only 87 (6%) such participants.</td>
    </tr>
    <tr>
       <td>†Using histopathologic definitions and focus score assessment methods as described by Daniels et al (1).</td>
    </tr>
    <tr>
       <td>‡Using ocular staining score as described by Whitcher et al (2).</td>
    </tr>
 </tbody>
 </table></p>
</div>
<div class="tabbed-block">
<p><br>
 <table class="md_basic_2">
 <thead>
    <tr class="header">
       <th>쇼그렌증후군 (SS)의 분류는, SS를 시사할 만한 징후나 증상이 있는 개인에게 적용하는데, 다음 세 가지 객관적 특징 중 최소 두 개 이상이 있는 환자에게 충족된다.</th>
    </tr>
 </thead>
 <tbody>
    <tr>
       <td> 1. 혈청 anti-SSA/Ro 양성 또는 anti-SSB/La 양성 또는 (RF 양성이면서 &amp; ANA titer ≥1:320)</td>
    </tr>
    <tr>
       <td> 2. 입술 침샘 조직검사상 focus score≥1 focus/4 mm2†을 동반한 국소 림프구성 침샘염</td>
    </tr>
    <tr>
       <td> 3. 안구 염색 점수 ≥3 인 건성각결막염<BR>(개인이 현재 녹내장에 대해 매일 점안액을 사용하지 않고 지난 5년 동안 각막 수술 또는 눈꺼풀 성형 수술을 받은 적이 없다고 가정)‡</td>
    </tr>
    </thead>
 <tbody>
    <tr class="blank">
       <td></td>
    </tr>
 </tbody>
 <thead>
    <tr>
       <th>이전에 다음 조건 중 어느 하나라도 진단된 적이 있다면, 임상 특징이 중복되거나 임상 검사와 간섭으로 인해 SS 연구나 치료적 임상시험에서 배제된다:</th>
    </tr>
 </thead>
 <tbody>
    <tr>
       <td>두경부 방사선 치료<BR>C형간염 감염<br>AIDS<br>사르코이드증<BR>아밀로이드증<BR>GVHD<BR>IgG4-연관 질환</td>
    </tr>
 </tbody>
 <tbody>
    <tr class=blank>
       <td colspan=2></td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.2)">
       <td colspan=2>Note</td>
    </tr>
    <tr>
       <td>*류마티스 관절염, 전신성 홍반성 루푸스, 경피증 및 기타 결합 조직 질환이 있는 참가자는 87명(6%)만 있었기 때문에 이러한 분석에서 제외함.</td>
    </tr>
    <tr>
       <td>†Daniels et al 가 설명한 조직병리 정의와 focus score 평가 방법</td>
    </tr>
    <tr>
       <td>‡Whitcher et al 가 설명한 안구 염색 점수 사용</td>
    </tr>
 </tbody>
 </table></p>
</div>
</div>
</div>
</details>
<details class="note"><summary>2002 AECG Primary Sjögren's Syndrome classification criteria</summary><div class="tabbed-set tabbed-alternate" data-tabs="3:2"><input checked="checked" id="__tabbed_3_1" name="__tabbed_3" type="radio" /><input id="__tabbed_3_2" name="__tabbed_3" type="radio" /><div class="tabbed-labels"><label for="__tabbed_3_1">ENG</label><label for="__tabbed_3_2">국문</label></div>
<div class="tabbed-content">
<div class="tabbed-block">
<p><br>
 <table class="md_basic_2">
 <thead>
    <tr class="header">
       <th>Revised Rules for Classification (2002 AECG)</th>
    </tr>
 </thead>
 <tbody>
    <tr style="background-color: rgba(0, 0, 0, 0.15);font-weight:bold">
       <td>For Primary SS: In patients without any potentially associated disease, primary SS may be defined as follows:</td>
    </tr>
    <tr>
       <td>a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV (Histopathology) or VI (Serology) is positive<br>b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI)<br>c. The classification tree procedure represents a valid alternative method for classification, although it should be more properly used in clinical-epidemiological survey</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.15);font-weight:bold">
       <td>For secondary SS: In patients with a potentially associated disease (for instance, another well defined connective tissue disease)</td>
    </tr>
    <tr>
       <td> the presence of item I or item II plus any 2 from among items III, IV, and V may be considered as indicative of secondary SS</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.15);font-weight:bold">
       <td>Exclusion Criteria</td>
    </tr>
    <tr>
       <td>Past head and neck radiation treatment<br>Hepatitis C infection<br>Acquired immunodeficiency disease (AIDS)<br>Pre-existing lymphoma<br>Sarcoidosis<br>Graft versus host disease<br>Use of anticholinergic drugs (since a time shorter than 4-fold the half life of the drug)</td>
    </tr></tbody><tbody>
    <tr class="blank">
       <td></td>
    </tr>
 </tbody>
 <thead>
    <tr class=header>
       <th>Classification criteria for Sjögren’s syndrome: revised
       version of the European criteria proposed by the American-European Consensus Group</th>
    </tr>
    <tr>
       <td style="font-weight:bold">Criteria</td>
    </tr>
 </thead>
 <tbody>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>I. Ocular symptoms: a positive response to at least one of the following questions:</td>
    </tr>
    <tr>
       <Td>&nbsp;&nbsp;1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?<Br> &nbsp;&nbsp;2. Do you have a recurrent sensation of sand or gravel in the eyes?<br> &nbsp;&nbsp;3. Do you use tear substitutes more than 3 times a day?</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>II. Oral symptoms: a positive response to at least one of the following questions:</td>
    </tr>
    <tr>
       <Td>&nbsp;&nbsp;1. Have you had a daily feeling of dry mouth for more than 3 months?<br> &nbsp;&nbsp;2. Have you had recurrently or persistently swollen salivary glands as an adult?<br> &nbsp;&nbsp;3. Do you frequently drink liquids to aid in swallowing dry food?</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>III. Ocular signs—that is, objective evidence of ocular involvement defined as a positive result for at least one of the following two tests:</td>
    </tr>
    <tr>
       <Td> &nbsp;&nbsp;1. Schirmer’s I test, performed without anaesthesia (≤5 mm in 5 minutes)<br>
          &nbsp;&nbsp;2. Rose bengal score or other ocular dye score (≥4 according to van Bijsterveld’s scoring system)<br></td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score&gt;1</td>
    </tr>
    <tr>
       <Td> &nbsp;&nbsp;focus score defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) per 4mm2 of glandular tissue</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at least one of the following
       diagnostic tests:</td>
    </tr>
    <tr>
       <Td>
       &nbsp;&nbsp;1. Unstimulated whole salivary flow (≤1.5 ml in 15 minutes)<br> &nbsp;&nbsp;2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or destructive pattern), without evidence of obstruction in the major ducts<br>&nbsp;&nbsp;3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer<br></td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>VI. Autoantibodies: presence in the serum of the following autoantibodies:</td>
    </tr>
    <tr>
       <Td> &nbsp;&nbsp;1. Antibodies to Ro(SSA) or La(SSB) antigens, or both</td>
    </tr>
 </tbody>
 </table></p>
</div>
<div class="tabbed-block">
<p><BR>
 <table class="md_basic_2">
 <thead>
    <tr class="header">
       <th>개정된 분류 규정 (2002 AECG)</th>
    </tr>
 </thead>
 <tbody>
    <tr style="background-color: rgba(0, 0, 0, 0.15);font-weight:bold">
       <td>일차성 SS: 환자들 중 잠재적으로 가능한 관련 질환이 없는 경우에, 일차성 SS은 다음과 같이 정의된다:</td>
    </tr>
    <tr>
       <td>a. IV (조직병리학) 또는 VI (혈청학) 두 가지 중 하나라도 양성이면서, 6개 항목 중 4개 항목이 있으면 일차성 SS를 시사한다.<br>b. 4가지 객관적 기준 항목 (III, IV, V, VI)중 3가지 항목 존재<br>c. 분류 트리 절차는 분류를 위한 유효한 대체 방법을 나타내는데, 다만 이 절차는 임상-역학 조사에서는 더 적절하게 사용되어야 한다.</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.15);font-weight:bold">
       <td>이차성 SS: 환자들 중 잠재적으로 가능한 관련 질환(예를 들어, 다른 결체 조직 질환)이 있는 경우 </td>
    </tr>
    <tr>
       <td> 항목 I 또는 항목 II에 항목 III, IV, V 중 두 가지가 있으면 이차성 SS를 나타내는 것으로 간주된다.</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.15);font-weight:bold">
       <td>배제 기준</td>
    </tr>
    <tr>
       <td>과거 두경부 방사선 치료<br>C형 간염 감염<br>AIDS<br>기존의 림프종<br>사르코이드증<br>GVHD<br>항콜린제 사용(약품 반감기의 4배보다 짧은 시간 이내)</td>
    </tr></tbody><tbody>
    <tr class="blank">
       <td></td>
    </tr>
 </tbody>
 <thead>
    <tr class=header>
       <th>Sjögren’s syndrome 분류 기준: AECG에서 제안한 유럽기준의 개정판 (2002)</th>
    </tr>
    <tr>
       <td style="font-weight:bold">항목</td>
    </tr>
 </thead>
 <tbody>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>I. 안구증상: 다음 질문 중 최소 1개 이상 양성 답변:</td>
    </tr>
    <tr>
       <Td>&nbsp;&nbsp;1. 3개월 이상 매일 지속되는 불편한 안구 건조증이 있는가?<Br> &nbsp;&nbsp;2. 눈에 모래나 자갈이 들어 있는 느낌이 반복적으로 발생하는가?<br> &nbsp;&nbsp;3. 하루에 3회 이상 인공눈물을 사용하는가?</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>II. 구강 증상: 다음 질문 중 최소 1개 이상 양성 답변:</td>
    </tr>
    <tr>
       <Td>&nbsp;&nbsp;1. 3개월 이상 매일 지속되는 구강 건조 증상이 있는가?<br> &nbsp;&nbsp;2. 성인기에 반복적이거나 지속적인 침샘비대가 생긴 적이 있는가?<br> &nbsp;&nbsp;3. 마른 음식을 삼킬 때 도움을 받기 위해 음료수를 자주 마시는가?</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>III. 안 검사 소견 - 객관적인 안구 침범의 증거로, 다음 두 검사 중 최소 한개에서 양성 결과인 것으로 정의됨:</td>
    </tr>
    <tr>
       <Td> &nbsp;&nbsp;1. 마취제를 사용하지 않고 시행한 Schirmer’s I 검사 (5분 동안 ≤5 mm)<br>
          &nbsp;&nbsp;2. Rose bengal score 또는 다른 안구 염색 점수 (van Bijsterveld 점수 ≥ 4)<br></td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>IV. 조직병리: 작은침샘 안의 (정상으로 보이는 점막에서 채취) 국소 림프구 침샘염이 전문 병리학자에 의해 평가되며, focus score≥1</td>
    </tr>
    <tr>
       <Td> &nbsp;&nbsp;focus score는 침샘 선조직 4mm2 당 림프구 foci (정상적으로 보이는 점액선에 인접하고 50개 이상의 림프구를 포함)의 수로 정의됨</td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>V. 침샘 침범: 객관적인 침샘 침범의 증거로, 다음 진단 검사 중 최소 한개에서 양성 결과인 것으로 정의됨:</td>
    </tr>
    <tr>
       <Td>
       &nbsp;&nbsp;1. 자극하지 않은 상태에서 전 타액 유속(15분 동안 ≤1.5 ml)<br> &nbsp;&nbsp;2. 이하선 침샘 조영술(Parotid sialography)상 주 침샘관 폐쇄 없이 미만성 침샘관 확장 (diffuse sialectasis) (구멍, 공동(cavitary) 또는  or 파괴 양상), <br>&nbsp;&nbsp;3. 침샘 스캔 (Salivary scintigraphy)상 표지자 (tracer)의 지연된 섭취, 농도 감소, 혹은 지연된 배출<br></td>
    </tr>
    <tr style="background-color: rgba(0, 0, 0, 0.08)">
       <td>VI. 자가항체: 다음 자가항체가 혈청 내에 존재:</td>
    </tr>
    <tr>
       <Td> &nbsp;&nbsp;1. Anti-Ro(SSA) 또는 Anti-La(SSB) 항체</td>
    </tr>
 </tbody>
 </table></p>
</div>
</div>
</div>
</details>
<ol>
<li>
<p>2002 AECG (IV or VI 만족할 때 4개 이상)</p>
</li>
<li>
<p>2012 SICCA &amp; ACR : 오로지 객관적인 검사에 근거함 (3 중 2개 이상) - too invasive!</p>
</li>
<li>
<p>2016 ACR/EULAR : 건조증상 + 기준 (9점 중 4점 이상)</p>
<p>** 2016 ACR/EULAR는 Anti-La Ab.를 분류기준에서 제외하고, OSS를 포함시킴.</p>
<p>** Rose bengal dye는 아프고 각막에 통증을 유발하기 때문에 제외함</p>
</li>
</ol>
<h3 id="6-5">6-5. 감별진단 (배제)</h3>
<ol>
<li>두경부 방사선치료 과거력, HCV, HIV, Sarcoidosis, amyloidosis, GVHD, IgG4-related ds.</li>
<li>약물 (항콜린작용), 직업 환경, 폐경 여부 등</li>
</ol>
<p><br></p>
<h2 id="7">7. 치료원칙</h2>
<details class="note"><summary>EULAR recommendations for the management of Sjögren’s syndrome (Overarching/Specific)</summary><div class="tabbed-set tabbed-alternate" data-tabs="4:3"><input checked="checked" id="__tabbed_4_1" name="__tabbed_4" type="radio" /><input id="__tabbed_4_2" name="__tabbed_4" type="radio" /><input id="__tabbed_4_3" name="__tabbed_4" type="radio" /><div class="tabbed-labels"><label for="__tabbed_4_1">ENG</label><label for="__tabbed_4_2">국문</label><label for="__tabbed_4_3">정의</label></div>
<div class="tabbed-content">
<div class="tabbed-block">
<p><br>
 <table class="md_basic_2">
 <colgroup>
 <col width="91%">
 <col width="3%">
 <col width="3%">
 <col width="3%">
 </colgroup>
 <thead>
 <tr class="header">
    <th colspan="4">Overarching (A-C) and Specific (1-12) Recommendations</th>
 </tr>
 <tr>
    <td></td>
    <td>LoE</td>
    <td>GoR</td>
    <td>LoA</td>
 </tr>
 </thead>
 <tbody>
 <tr>
    <td>A. Patients with SjS should be managed at, or in close collaboration with, centres of expertise following a multidisciplinary approach</td>
    <td>NA</td>
    <td>NA</td>
    <td>9.2</td>
 </tr>
 <tr>
    <td>B. The first therapeutic approach for dryness should be symptomatic relief using topical therapies</td>
    <td>NA</td>
    <td>NA</td>
    <td>8.9</td>
 </tr>
 <tr>
    <td>C. Systemic therapies may be considered for the treatment of active systemic disease</td>
    <td>NA</td>
    <td>NA</td>
    <td>9.1</td>
 </tr>
 <tr>
    <td>&nbsp;1. Baseline evaluation of salivary gland function is recommended before starting treatment for oral dryness</td>
    <td>5</td>
    <td>D</td>
    <td>8.7</td>
 </tr>
 <tr>
    <td>&nbsp;2. The preferred first therapeutic approach for oral dryness according to salivary gland function may be: </td>
    <td>1a/<em>1b</td>
    <td>B</td>
    <td>8.7</td>
 </tr>
 <tr>
    <td>&nbsp;&nbsp;&nbsp;2.1. Non-pharmacological stimulation for mild dysfunction;</td>
    <td></td>
    <td></td>
    <td></td>
 </tr>
 <tr>
    <td>&nbsp;&nbsp;&nbsp;2.2. Pharmacological stimulation</em> for moderate dysfunction;</td>
    <td></td>
    <td></td>
    <td></td>
 </tr>
 <tr>
    <td>&nbsp;&nbsp;&nbsp;2.3. Saliva substitution for severe dysfunction</td>
    <td></td>
    <td></td>
    <td></td>
 </tr>
 <tr>
    <td>&nbsp;3. The first-line therapeutic approach to ocular dryness includes the use of artificial tears and ocular gels/ointments</td>
    <td>1a</td>
    <td>B</td>
    <td>9.5</td>
 </tr>
 <tr>
    <td>&nbsp;4. Refractory/severe ocular dryness may be managed using topical immunosuppressive-containing drops<em> and autologous serum eye drops</td>
    <td>1a/</em>1b</td>
    <td>B/D</td>
    <td>9.1</td>
 </tr>
 <tr>
    <td>&nbsp;5. Concomitant diseases should be evaluated in patients presenting with fatigue/pain, whose severity should be scored using specific tools</td>
    <td>5</td>
    <td>D</td>
    <td>9.0</td>
 </tr>
 <tr>
    <td>&nbsp;6. Consider analgesics or other pain-modifying agents for musculoskeletal pain, considering the balance between potential benefits and side-effects</td>
    <td>4</td>
    <td>C</td>
    <td>8.9</td>
 </tr>
 <tr>
    <td>&nbsp;7. Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions</td>
    <td>4</td>
    <td>C</td>
    <td>9.0</td>
 </tr>
 <tr>
    <td>&nbsp;8. Glucocorticoids should be used at the minimum dose and length of time necessary to control active systemic disease </td>
    <td>4</td>
    <td>C</td>
    <td>9.6</td>
 </tr>
 <tr>
    <td>&nbsp;9. Immunosuppressive agents should be mainly used as GC-sparing agents, with no evidence supporting the choice of one agent over another</td>
    <td>4</td>
    <td>C</td>
    <td>8.9</td>
 </tr>
 <tr>
    <td>&nbsp;10. B-cell targeted therapies may be considered in patients with severe, refractory systemic disease</td>
    <td>1b</td>
    <td>B</td>
    <td>8.6</td>
 </tr>
 <tr>
    <td>&nbsp;11. The systemic organ-specific therapeutic approach may follow, as a general rule, the sequential (or combined) use of GCs, immunosuppressive agents and biologics</td>
    <td>5</td>
    <td>D</td>
    <td>8.6</td>
 </tr>
 <tr>
    <td>&nbsp;12. Treatment of B-cell lymphoma should be individualised according to the specific histological subtype and disease stage</td>
    <td>4</td>
    <td>C</td>
    <td>9.7</td>
 </tr>
 </tbody>
 <tbody>
 <tr class=blank><td colspan=4>LoE : Level of Evidence; GoR : Grade of Recommendation; Loa : Level of Agreement</td></tr>
 </table></p>
</div>
<div class="tabbed-block">
<p><br>
 <table class="md_basic_2">
 <colgroup>
 <col width="91%">
 <col width="3%">
 <col width="3%">
 <col width="3%">
 </colgroup>
 <thead>
 <tr class="header">
    <th colspan="4">포괄적(A-C) 및 구체적(1-12) 권장 사항</th>
 </tr>
 <tr>
    <td></td>
    <td>LoE</td>
    <td>GoR</td>
    <td>LoA</td>
 </tr>
 </thead>
 <tbody>
 <tr>
    <td>A. SjS 환자는 다학제적 접근법을 따르는 전문센터에서, 혹은 그 센터와 긴밀한 협력을 하면서 관리되어야 한다.</td>
    <td>NA</td>
    <td>NA</td>
    <td>9.2</td>
 </tr>
 <tr>
    <td>B. 건조 증상에 대한 첫번째 치료적 접근은 국소외용제를 사용한 증상 완화여야 한다.</td>
    <td>NA</td>
    <td>NA</td>
    <td>8.9</td>
 </tr>
 <tr>
    <td>C. 전신요법을 활동성 전신질환의 치료를 위해 고려할 수 있다.</td>
    <td>NA</td>
    <td>NA</td>
    <td>9.1</td>
 </tr>
 <tr>
    <td>&nbsp;1. 구강건조증 치료를 시작하기 전에 침샘기능의 기본상태를 평가하는 것이 추천된다.</td>
    <td>5</td>
    <td>D</td>
    <td>8.7</td>
 </tr>
 <tr>
    <td>&nbsp;2. 침샘기능에 따른 안구건조증에 대한 바람직한 첫 번째 치료법은 다음과 같다:</td>
    <td>1a/<em>1b</td>
    <td>B</td>
    <td>8.7</td>
 </tr>
 <tr>
    <td>&nbsp;&nbsp;&nbsp;2-1. 경증 기능장애에 대한 비약물적 자극</td>
    <td></td>
    <td></td>
    <td></td>
 </tr>
 <tr>
    <td>&nbsp;&nbsp;&nbsp;2-2. 중등도 기능장애에 대한 약물적 자극</td>
    <td></td>
    <td></td>
    <td></td>
 </tr>
 <tr>
    <td>&nbsp;&nbsp;&nbsp;2-3. 심한 기능장애에 대한 타액 대체제</td>
    <td></td>
    <td></td>
    <td></td>
 </tr>
 <tr>
    <td>&nbsp;3. 안구건조증의 1차적 치료 접근은 인공눈물과 안구 젤/연고 사용이 포함된다.</td>
    <td>1a</td>
    <td>B</td>
    <td>9.5</td>
 </tr>
 <tr>
    <td>&nbsp;4. 불응성/심한 안구건조증은 면역억제제를 함유한 국소 점안액</em>과 자가혈청점안액을 사용하여 조절할 수 있다.</td>
    <td>1a/*1b</td>
    <td>B/D</td>
    <td>9.1</td>
 </tr>
 <tr>
    <td>&nbsp;5. 동반 질환은 피로/통증이 있는 환자에서 평가되어야 하며, 특정한 도구를 사용하여 중증도를 평가해야 한다.</td>
    <td>5</td>
    <td>D</td>
    <td>9.0</td>
 </tr>
 <tr>
    <td>&nbsp;6. 근골격게 통증에 대해서는 진통제 또는 다른 통증조절제를 고려하되, 잠재적인 이점과 부작용 사이의 균형을 고려한다.</td>
    <td>4</td>
    <td>C</td>
    <td>8.9</td>
 </tr>
 <tr>
    <td>&nbsp;7. 전신 질환의 치료는 ESSDAI 정의를 사용하여 장기-특이적인  중증도에 맞게 맞춰져야 한다.</td>
    <td>4</td>
    <td>C</td>
    <td>9.0</td>
 </tr>
 <tr>
    <td>&nbsp;8. 글루코코르티코이드는 활동승 전신 질환을 조절하기 위해 필요한 최소 용량과 기간동안 사용해야 한다.</td>
    <td>4</td>
    <td>C</td>
    <td>9.6</td>
 </tr>
 <tr>
    <td>&nbsp;9. 면역억제제는 글루코코르티코이드를 감량하는 목적으로 주로 사용되어야 하며, 다른 제제보다 하나의 (특정) 제제의 선택을 뒷받침하는 증거는 없다.</td>
    <td>4</td>
    <td>C</td>
    <td>8.9</td>
 </tr>
 <tr>
    <td>&nbsp;10. B세포 표적 요법은 중증의 난치성 전신 질환 환자에게 고려해 볼 수 있다.</td>
    <td>1b</td>
    <td>B</td>
    <td>8.6</td>
 </tr>
 <tr>
    <td>&nbsp;11. 전신 장기 특이적 치료 접근법은, 일반적으로 글루코코르티코이드, 면역억제제 및 생물학적 제제를 순차적(또는 조합해서) 사용하는 방법을 따를 수 있다.</td>
    <td>5</td>
    <td>D</td>
    <td>8.6</td>
 </tr>
 <tr>
    <td>&nbsp;12. B세포 림프종의 치료는 특정 조직학적  아형과 질병 단계에 따라 개별화되어야 한다.</td>
    <td>4</td>
    <td>C</td>
    <td>9.7</td>
 </tr>
 </tbody>
 <tbody>
 <tr class=blank><td colspan=4>LoE : Level of Evidence; GoR : Grade of Recommendation; Loa : Level of Agreement</td></tr>
 </tbody>
 </table></p>
</div>
<div class="tabbed-block"></div>
</div>
</div>
</details>
<h3 id="7-1">7-1. 요약</h3>
<ol>
<li>건조 증상에 대해서는 pilocarpine이나 무가당 사탕, 인공 눈물 등의 보조제를 쓴다.</li>
<li>전신 증상에 대해서는 RA나 SLE에서 쓰는 약제와 유사한 약제를 사용한다.</li>
<li>MS : NSAIDs, HCQ, MTX, GC</li>
<li>Skin : Topical steroid, HCQ -&gt; MTX</li>
<li>Lung : ILD가 심하면 High dose GC, MMF, AZA</li>
</ol>
<h3 id="7-2-disease-activity-severity">7-2. Disease activity &amp; severity</h3>
<p>ESSDAI, ESSPRI</p>
<p><br></p>
<h2 id="8">8. 경과와 예후</h2>
<hr />
<ul>
<li><strong>low complement, cryoglobulinemia, vasculitis, lymphoma</strong> 등이 합병증으로 나타나면 사망률이 증가할 수 있다.</li>
</ul>
                
                  
                    

<hr>
<div class="md-source-date">
  <small>
    
      Last update: <span class="git-revision-date-localized-plugin git-revision-date-localized-plugin-date">November 1, 2021</span>
      
    
  </small>
</div>
                  
                
              
              
                


              
            </article>
          </div>
        </div>
        
          <a href="#" class="md-top md-icon" data-md-component="top" data-md-state="hidden">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12z"/></svg>
            Back to top
          </a>
        
      </main>
      
        
<footer class="md-footer">
  
    <nav class="md-footer__inner md-grid" aria-label="Footer">
      
        
        <a href="../../sle%26aps/aps/" class="md-footer__link md-footer__link--prev" aria-label="Previous: APS" rel="prev">
          <div class="md-footer__button md-icon">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
          </div>
          <div class="md-footer__title">
            <div class="md-ellipsis">
              <span class="md-footer__direction">
                Previous
              </span>
              APS
            </div>
          </div>
        </a>
      
      
        
        <a href="../../SSc/ssc/" class="md-footer__link md-footer__link--next" aria-label="Next: Systemic Sclerosis" rel="next">
          <div class="md-footer__title">
            <div class="md-ellipsis">
              <span class="md-footer__direction">
                Next
              </span>
              Systemic Sclerosis
            </div>
          </div>
          <div class="md-footer__button md-icon">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M4 11v2h12l-5.5 5.5 1.42 1.42L19.84 12l-7.92-7.92L10.5 5.5 16 11H4z"/></svg>
          </div>
        </a>
      
    </nav>
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-footer-copyright">
        
        
          Made with
          <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
            Material for MkDocs
          </a>
        
        
      </div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    <script id="__config" type="application/json">{"base": "../..", "features": ["navigation.tabs", "navigation.indexes", "navigation.top"], "translations": {"clipboard.copy": "Copy to clipboard", "clipboard.copied": "Copied to clipboard", "search.config.lang": "en", "search.config.pipeline": "trimmer, stopWordFilter", "search.config.separator": "[\\s\\-]+", "search.placeholder": "Search", "search.result.placeholder": "Type to start searching", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.term.missing": "Missing", "select.version.title": "Select version"}, "search": "../../assets/javascripts/workers/search.8397ff9e.min.js", "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.1e84347e.min.js"></script>
      
    
  </body>
</html>